{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:25:38Z","timestamp":1790277938767,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T00:00:00Z","timestamp":1533340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11910-018-0878-7","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T02:46:31Z","timestamp":1533350791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors"],"prefix":"10.1007","volume":"18","author":[{"given":"Justin C.","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adipong","family":"Brickshawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerin","family":"Liewluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,4]]},"reference":[{"key":"878_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/00000658-193701000-00015","volume":"105","author":"CG Burdick","year":"1937","unstructured":"Burdick CG. William Bradley Coley 1862-1936. Ann Surg. 1937;105:152\u20135.","journal-title":"Ann Surg"},{"key":"878_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227\u201342.","journal-title":"Nat Rev Immunol"},{"key":"878_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"878_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367.","journal-title":"Nat Rev Immunol"},{"key":"878_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.celrep.2016.10.042","volume":"17","author":"TT Jiang","year":"2016","unstructured":"Jiang TT, Martinov T, Xin L, Kinder JM, Spanier JA, Fife BT, et al. Programmed death-1 culls peripheral accumulation of high-affinity autoreactive CD4 T cells to protect against autoimmunity. Cell Rep. 2016;17:1783\u201394.","journal-title":"Cell Rep"},{"key":"878_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"878_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5:915\u20139.","journal-title":"Cancer Discov"},{"key":"878_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"\u2022 Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. A comprehensive review of cancer immunotherapy using immune checkpoint imhibitors.","journal-title":"Science"},{"key":"878_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1\/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27\u201341.","journal-title":"Cell Immunol"},{"key":"878_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol"},{"key":"878_CR11","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"878_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"\u2022\u2022 Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74:1216\u201322. A series of patients with PD-1 inhibitor-associated neurologic complications highlighting the breadth, diversity, and frequency of neuromuscular complications.","journal-title":"JAMA Neurol"},{"key":"878_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"\u2022\u2022 Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325. A series of patients with PD-1 inhibitor-associated neurologic complications highlighting the breadth, diversity, and frequency of neuromuscular complications.","journal-title":"Eur J Cancer"},{"key":"878_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"key":"878_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","volume":"41","author":"T Liewluck","year":"2018","unstructured":"\u2022\u2022 Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother. 2018;41:208\u201311. A series of patients with PD-1 inhibitor-associated immune-mediated myopathies highlighting a unique oculobulbar involvement in these patients, mimicking myasthenia gravis.","journal-title":"J Immunother"},{"key":"878_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","volume":"54","author":"KH Lau","year":"2016","unstructured":"Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54:157\u201361.","journal-title":"Muscle Nerve"},{"key":"878_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","volume":"27","author":"BH Nguyen","year":"2017","unstructured":"Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017;27:152\u20134.","journal-title":"Melanoma Res"},{"key":"878_CR18","doi-asserted-by":"crossref","first-page":"232470961667431","DOI":"10.1177\/2324709616674316","volume":"4","author":"SD Phadke","year":"2016","unstructured":"Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316.","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"6","key":"878_CR19","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1002\/mus.25496","volume":"55","author":"Iyad Alnahhas","year":"2017","unstructured":"Alnahhas I, Wong J. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve. 2017;55:E25-E26.","journal-title":"Muscle & Nerve"},{"key":"878_CR20","first-page":"119","volume":"78","author":"O Maeda","year":"2016","unstructured":"Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78:119\u201322.","journal-title":"Nagoya J Med Sci"},{"key":"878_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25055","volume":"54","author":"J Zhu","year":"2016","unstructured":"Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54:506\u20137.","journal-title":"Muscle Nerve"},{"key":"878_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25163","volume":"54","author":"P Polat","year":"2016","unstructured":"Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve. 2016;54:507.","journal-title":"Muscle Nerve"},{"key":"878_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25212","volume":"54","author":"G Sciacca","year":"2016","unstructured":"Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ, Zappia M. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve. 2016;54:507\u20139.","journal-title":"Muscle Nerve"},{"key":"878_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzalez","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27:266\u20138.","journal-title":"Neuromuscul Disord"},{"key":"878_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107:1055\u20138.","journal-title":"Cancer Sci"},{"key":"878_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","volume":"40","author":"E Chang","year":"2017","unstructured":"Chang E, Sabichi AL, Sada YH. Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother. 2017;40:114\u20136.","journal-title":"J Immunother"},{"key":"878_CR27","doi-asserted-by":"crossref","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2017;1078155216687389.","DOI":"10.1177\/1078155216687389"},{"key":"878_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","volume":"46","author":"T Shirai","year":"2016","unstructured":"Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46:86\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"878_CR29","first-page":"e1702","volume":"9","author":"JJ Mehta","year":"2017","unstructured":"Mehta JJ, Maloney E, Srinivasan S, Seitz P, Cannon M. Myasthenia gravis induced by nivolumab: a case report. Cureus. 2017;9:e1702.","journal-title":"Cureus"},{"key":"878_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","volume":"52","author":"AI Loochtan","year":"2015","unstructured":"Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 2015;52:307\u20138.","journal-title":"Muscle Nerve"},{"key":"878_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128\u201336.","journal-title":"Eur J Cancer"},{"key":"878_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3988\/jcn.2018.14.1.115","volume":"14","author":"SY Huh","year":"2018","unstructured":"Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY. Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol. 2018;14:115\u20137.","journal-title":"J Clin Neurol"},{"key":"878_CR33","doi-asserted-by":"publisher","first-page":"e7350","DOI":"10.1097\/MD.0000000000007350","volume":"96","author":"YH Chen","year":"2017","unstructured":"Chen YH, Liu FC, Hsu CH, Chian CF. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine (Baltimore). 2017;96:e7350.","journal-title":"Medicine (Baltimore)"},{"key":"878_CR34","doi-asserted-by":"publisher","first-page":"e9262","DOI":"10.1097\/MD.0000000000009262","volume":"96","author":"JH Chen","year":"2017","unstructured":"Chen JH, Lee KY, Hu CJ, Chung CC. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96:e9262.","journal-title":"Medicine (Baltimore)"},{"key":"878_CR35","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","volume":"12","author":"RYC Tan","year":"2017","unstructured":"Tan RYC, Toh CK, Takano A. Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis. J Thorac Oncol. 2017;12:e90\u20131.","journal-title":"J Thorac Oncol"},{"key":"878_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, et al. Neurologic complications of immune checkpoint inhibitors. J Neuro-Oncol. 2018;137:601\u20139.","journal-title":"J Neuro-Oncol"},{"issue":"11","key":"878_CR37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"Shigeaki Suzuki","year":"2017","unstructured":"\u2022\u2022 Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89:1127-34. A well-designed study of myasthenia gravis in nivolumab-treated patients highlighting the differences between myasthenia gravis patients with and without nivolumab exposure and the myasthenia gravis-myositis-myocarditis overlap syndrome.","journal-title":"Neurology"},{"key":"878_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"878_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","volume":"25","author":"ML Thibult","year":"2013","unstructured":"Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25:129\u201337.","journal-title":"Int Immunol"},{"key":"878_CR40","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","volume":"27","author":"H Vallet","year":"2016","unstructured":"Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016;27:1352\u20133.","journal-title":"Ann Oncol"},{"key":"878_CR41","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","volume":"66","author":"S Suzuki","year":"2009","unstructured":"Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009;66:1334\u20138.","journal-title":"Arch Neurol"},{"key":"878_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.autrev.2017.04.009","volume":"16","author":"E Santos","year":"2017","unstructured":"Santos E, Coutinho E, Martins da Silva A, Marinho A, Vasconcelos C, Taipa R, et al. Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: report of four cases and literature review. Autoimmun Rev. 2017;16:644\u20139.","journal-title":"Autoimmun Rev"},{"key":"878_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","volume":"4","author":"MA Bilen","year":"2016","unstructured":"Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36.","journal-title":"J Immunother Cancer"},{"key":"878_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-2004-829595","volume":"24","author":"VC Juel","year":"2004","unstructured":"Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24:75\u201381.","journal-title":"Semin Neurol"},{"key":"878_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141\u20139.","journal-title":"Muscle Nerve"},{"key":"878_CR46","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"878_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/kex346","volume":"57","author":"PC Gandiga","year":"2018","unstructured":"Gandiga PC, Wang AR, Gonzalez-Rivera T, Sreih AG. Pembrolizumab-associated inflammatory myopathy. Rheumatology (Oxford). 2018;57:397\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"878_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","volume":"387","author":"J Bourgeois-Vionnet","year":"2018","unstructured":"Bourgeois-Vionnet J, Joubert B, Bernard E, Sia MA, Pante V, Fabien N, et al. Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci. 2018;387:51\u20133.","journal-title":"J Neurol Sci"},{"key":"878_CR49","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1212\/NXI.0000000000000464","volume":"5","author":"N Uchio","year":"2018","unstructured":"Uchio N, Taira K, Ikenaga C, Unuma A, Kadoya M, Kubota A, et al. Granulomatous myositis induced by anti-PD-1 monoclonal antibodies. Neurol Neuroimmunol Neuroinflamm. 2018;5:e464.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"878_CR50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/1346-8138.12991","volume":"42","author":"M Yoshioka","year":"2015","unstructured":"Yoshioka M, Kambe N, Yamamoto Y, Suehiro K, Matsue H. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol. 2015;42:1008\u20139.","journal-title":"J Dermatol"},{"key":"878_CR51","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1634\/theoncologist.2016-0170","volume":"21","author":"E Fox","year":"2016","unstructured":"Fox E, Dabrow M, Ochsner G. A case of nivolumab-induced myositis. Oncologist. 2016;21:e3.","journal-title":"Oncologist"},{"key":"878_CR52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","volume":"40","author":"PT Diamantopoulos","year":"2017","unstructured":"Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother. 2017;40:221\u20133.","journal-title":"J Immunother"},{"key":"878_CR53","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1080\/10428194.2016.1265115","volume":"58","author":"L Saini","year":"2017","unstructured":"Saini L, Chua N. Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine. Leuk Lymphoma. 2017;58:2011\u20133.","journal-title":"Leuk Lymphoma"},{"key":"878_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","volume":"27","author":"J Behling","year":"2017","unstructured":"Behling J, Kaes J, Munzel T, Grabbe S, Loquai C. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res. 2017;27:155\u20138.","journal-title":"Melanoma Res"},{"key":"878_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","volume":"2","author":"L Min","year":"2014","unstructured":"Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2:15\u20138.","journal-title":"Cancer Immunol Res"},{"key":"878_CR56","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.mayocp.2016.12.025","volume":"92","author":"M Milone","year":"2017","unstructured":"Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc. 2017;92:826\u201337.","journal-title":"Mayo Clin Proc"},{"key":"878_CR57","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.","journal-title":"Lancet"},{"key":"878_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"878_CR59","first-page":"662","volume":"14","author":"KC Kahler","year":"2016","unstructured":"Kahler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14:662\u201381.","journal-title":"J Dtsch Dermatol Ges"},{"key":"878_CR60","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1002\/mus.25663","volume":"56","author":"MD Yost","year":"2017","unstructured":"Yost MD, Chou CZ, Botha H, Block MS, Liewluck T. Facial diplegia after pembrolizumab treatment. Muscle Nerve. 2017;56:E20\u20131.","journal-title":"Muscle Nerve"},{"issue":"1","key":"878_CR61","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1002\/mus.26101","volume":"58","author":"Stephanie Ong","year":"2018","unstructured":"Ong S, Chapman J, Young G, Mansy T. Guillain-Barre-like syndrome during pembrolizumab treatment. Muscle Nerve. 2018;58:E8-E10.","journal-title":"Muscle & Nerve"},{"key":"878_CR62","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","volume":"142","author":"A Jacob","year":"2016","unstructured":"Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S. A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016;142:1869\u201370.","journal-title":"J Cancer Res Clin Oncol"},{"key":"878_CR63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2340\/00015555-2548","volume":"97","author":"R Schneiderbauer","year":"2017","unstructured":"Schneiderbauer R, Schneiderbauer M, Wick W, Enk AH, Haenssle HA, Hassel JC. PD-1 antibody-induced Guillain-Barre syndrome in a patient with metastatic melanoma. Acta Derm Venereol. 2017;97:395\u20136.","journal-title":"Acta Derm Venereol"},{"key":"878_CR64","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF Maleissye de","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375:296\u20137.","journal-title":"N Engl J Med"},{"key":"878_CR65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/jnnp-2017-316510","volume":"89","author":"Y Fukumoto","year":"2018","unstructured":"Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry. 2018;89:435\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"878_CR66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0000000000000193","volume":"19","author":"S Supakornnumporn","year":"2017","unstructured":"Supakornnumporn S, Katirji B. Guillain-Barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis. 2017;19:80\u20133.","journal-title":"J Clin Neuromuscul Dis"},{"key":"878_CR67","first-page":"1241","volume":"20","author":"MM Dimachkie","year":"2014","unstructured":"Dimachkie MM, Saperstein DS. Acquired immune demyelinating neuropathies. Continuum (Minneap Minn). 2014;20:1241\u201360.","journal-title":"Continuum (Minneap Minn)"},{"key":"878_CR68","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jjco\/hyw090","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol. 2016;46:875\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"878_CR69","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/mus.25672","volume":"56","author":"M Sepulveda","year":"2017","unstructured":"Sepulveda M, Martinez-Hernandez E, Gaba L, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve. 2017;56:E162\u20137.","journal-title":"Muscle Nerve"},{"key":"878_CR70","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/annonc\/mdw613","volume":"28","author":"F Aya","year":"2017","unstructured":"Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-Gonz\u00e1lez S, Prat A, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2017;28:433\u20134.","journal-title":"Ann Oncol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-018-0878-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0878-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-018-0878-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:28:03Z","timestamp":1604719683000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-018-0878-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,4]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1007\/s11910-018-0878-7","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,4]]},"assertion":[{"value":"4 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Justin C. Kao, Adipong Brickshawana, and Teerin Liewluck declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"63"}}